Indies Pharma Jamaica Limited (JMSE: INDIES)
Jamaica
· Delayed Price · Currency is JMD 3.150
+0.120 (3.96%)
At close: Nov 29, 2024
Indies Pharma Jamaica Income Statement
Financials in millions JMD. Fiscal year is November - October.
Millions JMD. Fiscal year is Nov - Oct.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Jul '24 Jul 31, 2024 | Oct '23 Oct 31, 2023 | Oct '22 Oct 31, 2022 | Oct '21 Oct 31, 2021 | Oct '20 Oct 31, 2020 | Oct '19 Oct 31, 2019 | 2018 - 2016 |
| Revenue | 1,136 | 1,055 | 937.28 | 846.83 | 765.95 | 729.45 | Upgrade
|
| Revenue Growth (YoY) | 13.97% | 12.61% | 10.68% | 10.56% | 5.00% | 14.66% | Upgrade
|
| Cost of Revenue | 464.4 | 417.41 | 323.44 | 329.81 | 254.32 | 285.75 | Upgrade
|
| Gross Profit | 671.4 | 638.05 | 613.84 | 517.02 | 511.62 | 443.7 | Upgrade
|
| Selling, General & Admin | 340.49 | 308.57 | 273.53 | 244.65 | 243.65 | 287.13 | Upgrade
|
| Other Operating Expenses | -23.41 | -4.23 | 1.15 | 1.5 | -0.72 | 0.59 | Upgrade
|
| Operating Expenses | 380.56 | 367.82 | 332.13 | 299.61 | 294.42 | 307.58 | Upgrade
|
| Operating Income | 290.84 | 270.24 | 281.71 | 217.41 | 217.2 | 136.12 | Upgrade
|
| Interest Expense | -59.72 | -66.78 | -60.48 | -68.96 | -9.78 | -9.64 | Upgrade
|
| Interest & Investment Income | 1.46 | 1.46 | 0.95 | 4.84 | 0.52 | 0.32 | Upgrade
|
| Currency Exchange Gain (Loss) | 1.65 | 1.86 | -1.75 | 14.76 | 4.3 | 4.71 | Upgrade
|
| Other Non Operating Income (Expenses) | -3.29 | -3.29 | -2.22 | -2.59 | -3.46 | -3.66 | Upgrade
|
| EBT Excluding Unusual Items | 230.94 | 203.48 | 218.21 | 165.47 | 208.79 | 127.84 | Upgrade
|
| Gain (Loss) on Sale of Assets | 3.07 | 3.07 | 1.88 | 2.4 | - | - | Upgrade
|
| Pretax Income | 245.1 | 217.63 | 220.79 | 167.87 | 209.38 | 127.84 | Upgrade
|
| Income Tax Expense | 29.53 | 4.58 | - | - | 2.03 | -3.12 | Upgrade
|
| Net Income | 215.57 | 213.06 | 220.79 | 167.87 | 207.35 | 130.96 | Upgrade
|
| Net Income to Common | 215.57 | 213.06 | 220.79 | 167.87 | 207.35 | 130.96 | Upgrade
|
| Net Income Growth | 4.50% | -3.50% | 31.53% | -19.04% | 58.33% | 9.41% | Upgrade
|
| Shares Outstanding (Basic) | 1,347 | 1,333 | 1,333 | 1,333 | 1,333 | 1,333 | Upgrade
|
| Shares Outstanding (Diluted) | 1,347 | 1,333 | 1,333 | 1,333 | 1,333 | 1,333 | Upgrade
|
| Shares Change (YoY) | 1.57% | - | - | - | - | - | Upgrade
|
| EPS (Basic) | 0.16 | 0.16 | 0.17 | 0.13 | 0.16 | 0.10 | Upgrade
|
| EPS (Diluted) | 0.16 | 0.16 | 0.17 | 0.13 | 0.16 | 0.10 | Upgrade
|
| EPS Growth | 2.88% | -3.50% | 31.53% | -19.04% | 58.33% | 9.41% | Upgrade
|
| Free Cash Flow | 184.61 | 265.45 | 288.85 | 325.76 | -109.52 | 107.08 | Upgrade
|
| Free Cash Flow Per Share | 0.14 | 0.20 | 0.22 | 0.24 | -0.08 | 0.08 | Upgrade
|
| Dividend Per Share | 0.110 | 0.113 | 0.113 | 0.110 | 0.140 | - | Upgrade
|
| Dividend Growth | -2.91% | 0.27% | 2.73% | -21.43% | - | - | Upgrade
|
| Gross Margin | 59.11% | 60.45% | 65.49% | 61.05% | 66.80% | 60.83% | Upgrade
|
| Operating Margin | 25.61% | 25.60% | 30.06% | 25.67% | 28.36% | 18.66% | Upgrade
|
| Profit Margin | 18.98% | 20.19% | 23.56% | 19.82% | 27.07% | 17.95% | Upgrade
|
| Free Cash Flow Margin | 16.25% | 25.15% | 30.82% | 38.47% | -14.30% | 14.68% | Upgrade
|
| EBITDA | 279.11 | 289.13 | 300.95 | 233.54 | 228.5 | 148.38 | Upgrade
|
| EBITDA Margin | 24.57% | 27.39% | 32.11% | 27.58% | 29.83% | 20.34% | Upgrade
|
| D&A For EBITDA | -11.73 | 18.9 | 19.24 | 16.13 | 11.3 | 12.26 | Upgrade
|
| EBIT | 290.84 | 270.24 | 281.71 | 217.41 | 217.2 | 136.12 | Upgrade
|
| EBIT Margin | 25.61% | 25.60% | 30.06% | 25.67% | 28.36% | 18.66% | Upgrade
|
| Effective Tax Rate | 12.05% | 2.10% | - | - | 0.97% | - | Upgrade
|
| Advertising Expenses | - | 5.27 | 4.98 | 6.5 | 4.74 | 10.31 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.